Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Herantis Pharma

Related articles:
3/11/2024 12:55:15 PM - Herantis H2 2023: Presented positive phase I data - Redeye - Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week. We reiterate our positive view of the company.
12/6/2023 7:41:37 AM - Herantis Pharma: Directed issue completed - Redeye - Redeye endorses the recent news that Herantis has completed a directed issue of EUR4.5m at a price of EUR1.4 per share, to both existing and new shareholders, including the EIC fund (European Innovation Council). This should extend the company’s runway further (at least into 2025). The issue was close to our estimates (EUR5m at EUR1.35 per share) and we thus make no immediate changes to our valuation. We will soon return with a research update to further discuss the recent progress in the company, most notably the transformative phase I data.
10/26/2023 8:13:17 AM - Herantis Pharma: Announces positive phase Ia data - Redeye - Redeye is positive towards the top-line data from the phase Ia trial with HER-096 presented by Herantis. We raise our base case and look forward to an exciting 2024.
10/25/2023 11:43:19 AM - Herantis Pharma: Announces positive phase Ia data - Redeye - Redeye endorses today’s news that Herantis has presented positive phase Ia data with HER-096, and the company states that “The clinical trial demonstrated favorable safety and tolerability, fast uptake of HER-096, and significant HER-096 concentrations in the cerebrospinal fluid (CSF) after a single subcutaneous injection.” We will participate during the webinar that will start shortly and then return with an additional take, where we expect to raise our base case.
9/25/2023 7:04:38 AM - Herantis: Receives waive-off from Business Finland for development loan - Redeye - Redeye endorses yesterday’s news that Business Finland has waived-off around EUR4.5m of the principal amount from a development loan focusing on CDNF. According to the release, Herantis will no longer have any loans from Business Finland after a final payment of EUR40 thousand. We make no immediate adjustments to our valuation but welcome this decision that strengthens the company’s balance sheet substantially. We look forward to the phase Ia top-line data expected in Q4 this year.
8/25/2023 12:21:22 PM - Herantis H1 2023: Progress in the clinic - Redeye - Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H1 report. We continue to see an interesting case going forward and are are excited to see that Herantis now again is a clinical stage company.
8/22/2023 10:04:52 AM - Herantis Pharma: First healthy volunteers have been dosed in the second part of the phase Ia trial with HER-096 - Redeye - Redeye endorses today’s news that the first healthy volunteers have been dosed in the second part of the phase Ia trial with HER-096. In this section of the trial, “12-16 elderly healthy volunteers, both males and females, will be administered with a single dose of HER-096 to evaluate the blood-brain-barrier penetration of HER-096”. The company expects to present top-line data in Q4 this year. We are encouraged to learn that the trial is progressing well and will return with a more thorough comment in relation the report later this week.
4/19/2023 9:18:22 AM - Herantis Pharma: First healthy volunteer dosed in phase I trial - Redeye - Redeye is encouraged to learn that the first healthy volunteer has been dosed in the company’s phase Ia trial (n=60) with HER-096.The goal is to evaluate safety, tolerability, and blood-brain barrier penetration. In today’s release, the company reiterates its guidance that top-line data is to be expected before the end of 2023. We have seen the step back into the clinic as an important milestone and conclude that Herantis once again is a clinical-stage company. We reiterate our valuation for now and look forward to the results later this year.
4/12/2023 9:42:18 AM - Herantis Pharma: Signed grant agreement with European Innovation Council (EIC) - Redeye - Redeye endorses today’s news that Herantis has signed the grant agreement with the European Innovation Council (EIC) Accelerator. Herantis will receive EUR2.5m in grant funding and is eligible for up to EUR15m in direct equity investment from the EIC fund. We see this both as a validation of the quality of the science within Herantis and as a welcome capital injection, which further demonstrates the company’s strong ability to raise capital in an efficient manner. Herantis states that this will enable the company to start preparations for the next development phase sooner than anticipated. Following the announcement in December, we have assumed that the company will receive the grant and make no immediate adjustments. Looking forward, we think it will be interesting to follow the negotiations ahead regarding a potential equity investment - which further could support the company's critical journey ahead.
3/3/2023 8:13:11 AM - Herantis H2 2022: Important progress - Redeye - Redeye returns with a research update following Herantis H2 report. We slightly raise our base case and expect Herantis to take the important step back into the clinic now in H1 2023.
2/20/2023 2:38:03 PM - Herantis: Approval to start phase I study with HER-096 - Redeye - Redeye endorses today’s news that Herantis has received approval to start its phase I study with HER-096 in healthy volunteers. To us, the step back into the clinic has been an important milestone and we like that the timeline continues to be followed. We will discuss the trial further in relation to the H2 report.
1/9/2023 12:31:58 PM - Herantis Pharma: Soon again a (stronger) clinical company - Redeye - Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– an engineered derivative of its previous lead drug CDNF that allows for non-invasive administration. We slightly raise our base case to SEK 24 per share (22) and expect Herantis to take the important step back into the clinic now in H1 2023.
12/20/2022 7:49:56 AM - Herantis: Submitted Clinical Trial Application (CTA) - Redeye - Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I study with its lead candidate HER-096 targeting Parkinson’s disease. Herantis reiterates its guidance to initiate the study in H1 2023, pending approval. We will return with a research update in early January to discuss the study in-depth.
8/26/2022 10:11:30 AM - Herantis Pharma: Our H1 Comment - Redeye - Redeye comments on yesterday’s H1 report from Herantis and we reiterate our view of the company.
7/11/2022 7:34:20 AM - Herantis Pharma: Antti Vuolanto Appointed as CEO - Redeye - Redeye has a positive take on the news that Antti Vuolanto, currently COO, has been named as CEO of Herantis.
6/16/2022 10:16:53 AM - Herantis Pharma: Summary of Recent Events and Updated Base Case - Redeye - Redeye comments on the recent news in the company and adjust for the recent capital injections in the company.
3/30/2022 2:18:18 PM - Herantis Pharma: Rights Issue(s) Announced - Redeye - Redeye comments on the news that Herantis has carried out a directed issue and announced the intention to carry out a rights issue worth in total EUR 8.7 million. We give our initial take and will return at a later stage to adjust our fair value range.
3/4/2022 8:03:21 AM - Herantis Pharma: Our H2 Comment - Redeye - Redeye comments on the H2 report from Herantis Pharma and reiterate our view of the company.
1/21/2022 8:15:50 AM - Herantis: CEO Change and Focused Strategy on xCDNF - Redeye - Redeye comments on yesterday’s CEO change in Herantis and announcement of strategy shift towards its next generation xCDNF program.
10/28/2021 8:18:46 AM - Herantis Pharma: A (Small) Pivot to xCDNF - Redeye - Redeye has an overall positive take on the progress presented at yesterday’s R&D Seminar. We give our view of the way forward for Herantis lead projects addressing Parkinson’s Disease (rhCDNF and HER-096).
9/16/2021 10:05:21 AM - Herantis Pharma: Comment on Directed Share Issue - Redeye - Redeye comments on yesterday’s directed share issue of EUR 4 million.
9/9/2021 5:45:26 AM - Herantis Pharma: A look back at H1’21 - ABG - Summary of events in H1’21<br>Updated model following refocusing on CNS<br>Upcoming milestones
8/26/2021 2:19:15 PM - Herantis Pharma: Our H1 Comment - Redeye - Redeye comments on the H1 report from Herantis Pharma. We provide a brief comment on the financials and highlight the most important events during the period.
5/31/2021 2:06:16 PM - Herantis Pharma: xCDNF Candidate Selection – Check - Redeye - Herantis Pharma announced today that the company has selected HER-096 as lead candidate for its non-invasive xCNDF program. We give our take on the positive news.
5/18/2021 2:26:18 PM - Herantis Pharma: Multimodal Potential - Redeye - Redeye initiates coverage of Herantis Pharma, a biotech developing drug candidates in the difficult area of Parkinson’s, an area with great potential to improve the standard of care. The case hinges on blockbuster potential in this expanding market, supported by experienced management, institutional ownership and a prospective licensing deal. While the share trades close to fair value, longer-term upside is compelling.
2/9/2021 7:06:15 AM - Nanoform och Herantis Pharma tecknar Proof of Concept-avtal - Nanoform och Herantis Pharma har tecknat ett så kallat Biologics Proof of Concept-avtal, enligt ett pressmeddelande.
12/18/2020 7:20:07 AM - Nanoform ingår samarbete med Herantis på nya biologiska sidan - Nanoform har tecknat en avsiktsförklaring med läkemedelsbolaget Herantis kring att utforska så kallad BBB-penetration av CDNF- och XCDNF-molekylerna från Herantis. Samarbetet bygger på Nanoforms senaste plattformsteknologi för biologiska läkemedel. Det framgår av ett pressmeddelande. Båda bolagen är börsnoterade på First North.
10/3/2019 2:39:32 PM - Dizlin och Herantis – två Parkinsonbolag på väg till svenska börsen - Dizlin och Herantis – två Parkinsonbolag på väg till svenska börsen